BrightPath Biotherapeutics Co Ltd banner
B

BrightPath Biotherapeutics Co Ltd
TSE:4594

Watchlist Manager
BrightPath Biotherapeutics Co Ltd
TSE:4594
Watchlist
Price: 55 JPY 7.84%
Market Cap: ¥7.6B

Intrinsic Value

The intrinsic value for BrightPath Biotherapeutics Co Ltd (4594) under the Base Case is 15.1 JPY. Compared with the current market price of 55 JPY, the stock appears Overvalued by 73% .

Intrinsic value calculated using DCF
¥15.1
Other reference points

Do our valuations actually work? See backtest results .

Intrinsic Value
¥15.1
Overvaluation 73%
Intrinsic Value
Price ¥55
B
Monitor BrightPath Biotherapeutics Co Ltd
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value ¥12.08
Get notified when the price drops into your buy zone
Current Price ¥55
Intrinsic Value ¥15.1
Margin of Safety 20% ¥12.08
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about BrightPath Biotherapeutics Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BrightPath Biotherapeutics Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for BrightPath Biotherapeutics Co Ltd.

Explain Valuation
Alternatives to BrightPath Biotherapeutics Co Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one BrightPath Biotherapeutics Co Ltd stock?

The intrinsic value for BrightPath Biotherapeutics Co Ltd (4594) under the Base Case is 15.1 JPY.

Is BrightPath Biotherapeutics Co Ltd stock undervalued or overvalued?

Compared with the current market price of 55 JPY, the stock appears Overvalued by 73% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett